What is Orthox?
Orthox develops innovative tissue regenerative implants designed to treat significant cartilage damage, a condition often preceding osteoarthritis. Founded in 2008 and headquartered in the United Kingdom, the company is positioned within the burgeoning field of regenerative medicine. Its focus on cartilage repair addresses a critical unmet need in orthopedic care, aiming to improve patient outcomes and potentially delay or prevent the progression of degenerative joint diseases. The company's technology represents a significant advancement in biomaterials and tissue engineering.
How much funding has Orthox raised?
Orthox has raised a total of $12.5M across 1 funding round:
Series A
$12.5M
Series A (2022): $12.5M with participation from Additio Investment Group, Parkwalk Advisors, and Oxford Technology & Innovations EIS Fund
Key Investors in Orthox
Additio Investment Group
Additio Investment Group is a venture capital firm specializing in value creation for Healthcare and Life Sciences ventures, with a focus on innovative EU-based opportunities in the Seed and A round stages, particularly in MedTech, Digital Health/HealthTech, and Bio/Pharma sectors.
Parkwalk Advisors
Parkwalk Advisors is a leading investor in university spinouts, focusing on deeptech innovations emerging from the UK's top universities, providing funding and expertise to help these companies thrive.
Oxford Technology & Innovations EIS Fund
Undisclosed investor participating in the funding round.
What's next for Orthox?
The recent major enterprise-level funding, characterized as a strategic investment, signals a pivotal growth phase for Orthox. This capital is expected to accelerate product development, expand clinical trials, and scale manufacturing capabilities to meet growing market demand. The involvement of sophisticated investors suggests a strong belief in Orthox's technology and its potential to capture a substantial share of the orthopedic regenerative medicine market. Future strategic initiatives will likely focus on market penetration, regulatory approvals in key global markets, and further innovation in implantable biomaterials.
See full Orthox company page
